On the stock market since 2017, it operates in the world of health and science. It has 2,839 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year). Red columns mark years that ended in a loss.
The gap is $341.8M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, GUERF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GUERF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.